The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer

被引：79

作者：

Pan, Yue ^{[1
]}

Deng, Chao ^{[1
]}

Qiu, Zhenhua ^{[1
]}

Cao, Chenghui ^{[2
]}

Wu, Fang ^{[1
,3
,4
,5
]}

机构：

[1] Cent South Univ, Xiangya Hosp 2, Dept Oncol, Changsha, Peoples R China

[2] Cent South Univ, Changsha, Peoples R China

[3] Hunan Canc Mega Data Intelligent Applicat & Engn, Changsha, Peoples R China

[4] Cent South Univ, Xiangya Hosp 2, Hunan Key Lab Tumor Models & Individualized Med, Changsha, Peoples R China

[5] Cent South Univ, Xiangya Hosp 2, Hunan Key Lab Early Diag & Precise Treatment Lung, Changsha, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2021年 / 11卷

关键词：

anaplastic lymphoma kinase (ALK); TKI; tyrosine kinase inhibitor; resistance; NSCLC; therapy; MUTATION CONFERS RESISTANCE; POSITIVE NSCLC PATIENTS; TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; OPEN-LABEL; HISTOLOGICAL TRANSFORMATION; CRIZOTINIB RESISTANCE; ANTITUMOR-ACTIVITY; CLINICAL-FEATURES; BRAIN METASTASES;

D O I：

10.3389/fonc.2021.713530

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Anaplastic lymphoma kinase (ALK) is a validated molecular target for non-small-cell lung cancer (NSCLC). The use of tyrosine kinase inhibitors (TKIs) has led to significantly improved survival benefits. However, the clinical benefits of targeting ALK using TKIs are limited due to the emergence of drug resistance. The landscape of resistance mechanisms and treatment decisions has become increasingly complex. Therefore, continued research into new drugs and combinatorial therapies is required to improve outcomes in NSCLC. In this review, we explore the resistance mechanisms of ALK TKIs in advanced NSCLC in order to provide a theoretical basis and research ideas for solving the problem of ALK drug resistance.

引用

页数：13

共 138 条

[1] Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient [J].

Ai, Xinghao ;

Niu, Xiaomin ;

Chang, Lianpeng ;

Chen, Rongrong ;

Ou, Sai-Hong Ignatius ;

Lu, Shun .

LUNG CANCER, 2018, 123 :83-86

[2] OPINION Challenges in circulating tumour cell research [J].

Alix-Panabieres, Catherine ;

Pantel, Klaus .

NATURE REVIEWS CANCER, 2014, 14 (09) :623-631

[3] Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer [J].

Arai, Sachiko ;

Takeuchi, Shinji ;

Fukuda, Koji ;

Taniguchi, Hirokazu ;

Nishiyama, Akihiro ;

Tanimoto, Azusa ;

Satouchi, Miyako ;

Yamashita, Kaname ;

Ohtsubo, Koshiro ;

Nanjo, Shigeki ;

Kumagai, Toru ;

Katayama, Ryohei ;

Nishio, Makoto ;

Zheng, Mei-mei ;

Wu, Yi-Long ;

Nishihara, Hiroshi ;

Yamamoto, Takushi ;

Nakada, Mitsutoshi ;

Yano, Seiji .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (05) :752-765

[4] Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer [J].

Blackhall, Fiona ;

Camidge, D. Ross ;

Shaw, Alice T. ;

Soria, Jean-Charles ;

Solomon, Benjamin J. ;

Mok, Tony ;

Hirsh, Vera ;

Jaenne, Pasi A. ;

Shi, Yuankai ;

Yang, Pan-Chyr ;

De Pas, Tommaso ;

Hida, Toyoaki ;

De Castro Carpeno, Javier ;

Lanzalone, Silvana ;

Polli, Anna ;

Iyer, Shrividya ;

Reisman, Arlene ;

Wilner, Keith D. ;

Kim, Dong-Wan .

ESMO OPEN, 2017, 2 (03)

[5] Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non-Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses [J].

Blumenthal, Gideon M. ;

Karuri, Stella W. ;

Zhang, Hui ;

Zhang, Lijun ;

Khozin, Sean ;

Kazandjian, Dickran ;

Tang, Shenghui ;

Sridhara, Rajeshwari ;

Keegan, Patricia ;

Pazdur, Richard .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) :1008-+

[6]

Camidge DR, 2020, J CLIN ONCOL, V38

[7] Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial [J].

Camidge, D. Ross ;

Kim, Hye Ryun ;

Ahn, Myung-Ju ;

Yang, James C. H. ;

Han, Ji-Youn ;

Hochmair, Maximilian J. ;

Lee, Ki Hyeong ;

Delmonte, Angelo ;

Garcia Campelo, Maria Rosario ;

Kim, Dong-Wan ;

Griesinger, Frank ;

Felip, Enriqueta ;

Califano, Raffaele ;

Spira, Alexander ;

Gettinger, Scott N. ;

Tiseo, Marcello ;

Lin, Huamao M. ;

Gupta, Neeraj ;

Hanley, Michael J. ;

Ni, Quanhong ;

Zhang, Pingkuan ;

Popat, Sanjay .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) :3592-+

[8] Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study [J].

Camidge, D. Ross ;

Dziadziuszko, Rafal ;

Peters, Solange ;

Mok, Tony ;

Noe, Johannes ;

Nowicka, Malgorzata ;

Gadgeel, Shirish M. ;

Cheema, Parneet ;

Pavlakis, Nick ;

de Marinis, Filippo ;

Cho, Byoung Chul ;

Zhang, Li ;

Moro-Sibilot, Denis ;

Liu, Ting ;

Bordogna, Walter ;

Balas, Bogdana ;

Mueller, Barbara ;

Shaw, Alice T. .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (07) :1233-1243

[9] Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials [J].

Camidge, D. Ross ;

Kim, Dong-Wan ;

Tiseo, Marcello ;

Langer, Corey J. ;

Ahn, Myung-Ju ;

Shaw, Alice T. ;

Huber, Rudolf M. ;

Hochmair, Maximilian J. ;

Lee, Dae Ho ;

Bazhenova, Lyudmila A. ;

Gold, Kathryn A. ;

Ou, Sai-Hong Ignatius ;

West, Howard L. ;

Reichmann, William ;

Haney, Jeff ;

Clackson, Tim ;

Kerstein, David ;

Gettinger, Scott N. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (26) :2693-+

[10] Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1 [J].

Chen, Hengyi ;

Lin, Caiyu ;

Peng, Tao ;

Hu, Cheng ;

Lu, Conghua ;

Li, Li ;

Wang, Yubo ;

Han, Rui ;

Feng, Mingxia ;

Sun, FenFen ;

He, Yong .

CELL DEATH & DISEASE, 2020, 11 (02)

← 1 2 3 4 5 6 7 8 9 10 →